Navigation Links
Study Shows Machine Perfusion Significantly Improves Transplant Results
Date:12/31/2008

global medical technology company with European headquarters in Brussels. Organ Recovery Systems develops advanced perfusion techniques to improve the quality and quantity of organs, tissues and cells for transplantation. Working with a team of leading transplant professionals, Organ Recovery Systems develops medical devices, chemical solutions and techniques to improve the process by which cells, tissues and organs are treated -- from the time of donation to the time of transplantation.

Organ Recovery Systems initial product is the LifePort Kidney Transporter. During its pilot introduction phase, 270 LifePorts have perfused more than 12,000 kidneys in transplant programs worldwide. Medical devices for ex vivo preservation of the heart, lung, pancreas and liver are in pre-clinical development.


'/>"/>
SOURCE Organ Recovery Systems
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
2. New study indicates smallpox vaccination effective for decades
3. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
4. Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury
5. QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy
6. Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD
7. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
8. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
9. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
10. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
11. Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") ... science-based research and development, sales and marketing of ... announced today that it is awarding exclusive Vestiage ... of Reluma Skin Illuminating Facial Care. Qualified applicants ... sending an email to info(at)vestiageinc(dot)com and putting RELUMA ...
(Date:5/23/2013)... CAMBRIDGE, England , May 24, 2013 ... von Mundipharma angefertigt – Bei der ... Version , 91 % der Teilnehmer einer ... obwohl nur 20 % laut GINA [*] -Definition [1] ... zeigt, dass Menschen mit Asthma generell einer von vier ...
(Date:5/23/2013)... 23, 2013 Venaxis, Inc. (Nasdaq:   APPY), ... obtaining FDA clearance and commercializing its rapid, protein biomarker-based ... of an underwritten public offering of 10,000,000 shares of ... shares of its common stock at an exercise price ... price of $1.25 per share and related warrant.  Venaxis ...
(Date:5/23/2013)... 23, 2013 Can economic incentives such ... motivate members of the public to increase their donations ... Johns Hopkins Carey Business School Assistant Professor Mario ... to a large body of recent research that supports ... 24, 2013, issue of Science that the World Health ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3
... Reaching First Clinical Milestone Validates Approach, SAN ... successful completion of its first clinical trial, a,proof-of-concept ... a sodium channel blocker. Rufinamide was discovered and,developed ... in Europe as a,drug to treat a form ...
... January 22 Arpida Ltd.,(SWX: ARPN) announced today that ... with the TLT treatment in onychomycosis has been,initiated and ... 220 patients in total will be enrolled in this ... interest to,participate well in advance of the trial., ...
... nation,s top-10 GPOs(1), IRVINE, Calif., Jan. ... and Read-Through Motion and Low Perfusion pulse,oximetry, ... supplier agreement,with HealthTrust Purchasing Group (HealthTrust), representing ... ambulatory surgery,centers, alternate care sites and physician ...
Cached Biology Technology:Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 2Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 3Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis 2Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis 3Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis 4Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group 2Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group 3Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group 4
(Date:5/22/2013)... engineering drastically reduces the time and effort needed ... of biotechnology, scientists are reporting. Published in the ... paves the way for more rapid development of ... other activities. , Keith Shearwin and colleagues explain ... genetic material DNA into a bacterium,s genome is ...
(Date:5/22/2013)... in cellular DNA can endanger the whole organism, as ... at Ludwig-Maximilians-Universitaet (LMU) in Munich now report how byproducts ... helix. , The DNA in our cells controls the ... bodies. The instructions for this are encoded in the ... the bases adenine (A), cytosine (C), guanine (G) and ...
(Date:5/22/2013)... important new details on how climate change will affect ... in the Journal of Animal Ecology . This ... and informing policymakers of how species are likely to ... is a growing recognition among biologists that climate change ... that this is going to have very important consequences ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5
... this year, says the American Cancer Society, and 10,000 ... in the early stages, melanoma can be a particularly ... an efficiency that few tumors possess. Now, researchers at ... the reasons why this particular skin tumor is so ...
... Hopkins have discovered the presence of functional ion channels ... act like electrical wires and permit ESCs, versatile cells ... types of the body, to conduct and pass along ... of these channels in implanted cells, derived from stem ...
... pathogenic fungi as model systems for understanding fungal diseases, ... offers insight into how carbon dioxide (CO2) governs the ... different environments and invade the human body, and they ... utilize evolutionarily conserved enzymes to control the growth and ...
Cached Biology News:Researchers discover why melanoma is so malignant 2Researchers discover why melanoma is so malignant 3Stem cells' electric abilities might help their safe clinical use 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 3
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
...
...
...
Biology Products: